Intraocular lymphoma in Korea: The Consortium for Improving Survival of Lymphoma (CISL) study

Seul Lee, Moon Jin Kim, Jin Seok Kim, Sung Yong Oh, Seok Jin Kim, Yoon Hyung Kwon, In Young Chung, Jung Hun Kang, Deok Hwan Yang, Hye Jin Kang, Dok Hyun Yoon, Won Seog Kim, Hyo Jin Kim, Cheolwon Suh

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background Intraocular lymphoma (IOL) is a rare malignant lymphoma that most closely resemblesa diffuse large B-cell lymphoma, and it is a subtype of primary central nervous systemlymphoma (PCNSL). IOL is located inside the eye in the retina, uvea, and/or optic nerve. We retrospectively analyzed IOL patient data to identify treatment patterns and survivalrates in Korea. Methods Cytological confirmation for a diagnosis of IOL was performed for all patients. The clinicaldata collected from medical records included Ann Arbor stage, International Prognostic Index, performance status, date of diagnosis, treatment modality and response, date of relapse, and date of last follow-up. Results Twenty patients who were diagnosed with IOL, between December 2007 and June 2014 at multiple centers in Korea, were included in the analysis. Four patients were diagnosed with IOL alone, not involving the CNS. Two patients with isolated IOL later developed PCNSL. Nine patients developed CNS lesions before the onset of ocular lymphoma. Fivepatients had simultaneous onset in the eye and CNS. Twelve patients were treated by intravitreal injection of methotrexate for IOL. The median progression-free survival (PFS) forpatients was 19.7 months (95% CI, 8.7-30.7 mo). The estimated 3-year overall survival(OS) for all patients was 75.1%. Conclusion Treatment for IOL patients included radiotherapy and intraocular chemotherapy. IOL patients showed favorable PFS and OS. These patients would require long-term follow-upto identify relapse and adverse effects of radiotherapy or intraocular chemotherapy.

Original languageEnglish
Pages (from-to)242-247
Number of pages6
JournalBlood Research
Volume50
Issue number4
DOIs
Publication statusPublished - 2015 Jan 1

Fingerprint

Intraocular Lymphoma
Korea
Lymphoma
Survival
Disease-Free Survival
Radiotherapy
Uvea
Recurrence
Drug Therapy
Intravitreal Injections
Lymphoma, Large B-Cell, Diffuse
Optic Nerve
Methotrexate
Medical Records

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Lee, Seul ; Kim, Moon Jin ; Kim, Jin Seok ; Oh, Sung Yong ; Kim, Seok Jin ; Kwon, Yoon Hyung ; Chung, In Young ; Kang, Jung Hun ; Yang, Deok Hwan ; Kang, Hye Jin ; Yoon, Dok Hyun ; Kim, Won Seog ; Kim, Hyo Jin ; Suh, Cheolwon. / Intraocular lymphoma in Korea : The Consortium for Improving Survival of Lymphoma (CISL) study. In: Blood Research. 2015 ; Vol. 50, No. 4. pp. 242-247.
@article{05c199a5c568414588c216bdd5269787,
title = "Intraocular lymphoma in Korea: The Consortium for Improving Survival of Lymphoma (CISL) study",
abstract = "Background Intraocular lymphoma (IOL) is a rare malignant lymphoma that most closely resemblesa diffuse large B-cell lymphoma, and it is a subtype of primary central nervous systemlymphoma (PCNSL). IOL is located inside the eye in the retina, uvea, and/or optic nerve. We retrospectively analyzed IOL patient data to identify treatment patterns and survivalrates in Korea. Methods Cytological confirmation for a diagnosis of IOL was performed for all patients. The clinicaldata collected from medical records included Ann Arbor stage, International Prognostic Index, performance status, date of diagnosis, treatment modality and response, date of relapse, and date of last follow-up. Results Twenty patients who were diagnosed with IOL, between December 2007 and June 2014 at multiple centers in Korea, were included in the analysis. Four patients were diagnosed with IOL alone, not involving the CNS. Two patients with isolated IOL later developed PCNSL. Nine patients developed CNS lesions before the onset of ocular lymphoma. Fivepatients had simultaneous onset in the eye and CNS. Twelve patients were treated by intravitreal injection of methotrexate for IOL. The median progression-free survival (PFS) forpatients was 19.7 months (95{\%} CI, 8.7-30.7 mo). The estimated 3-year overall survival(OS) for all patients was 75.1{\%}. Conclusion Treatment for IOL patients included radiotherapy and intraocular chemotherapy. IOL patients showed favorable PFS and OS. These patients would require long-term follow-upto identify relapse and adverse effects of radiotherapy or intraocular chemotherapy.",
author = "Seul Lee and Kim, {Moon Jin} and Kim, {Jin Seok} and Oh, {Sung Yong} and Kim, {Seok Jin} and Kwon, {Yoon Hyung} and Chung, {In Young} and Kang, {Jung Hun} and Yang, {Deok Hwan} and Kang, {Hye Jin} and Yoon, {Dok Hyun} and Kim, {Won Seog} and Kim, {Hyo Jin} and Cheolwon Suh",
year = "2015",
month = "1",
day = "1",
doi = "10.5045/br.2015.50.4.242",
language = "English",
volume = "50",
pages = "242--247",
journal = "Blood Research",
issn = "2287-979X",
publisher = "Korean Society of Hematology",
number = "4",

}

Lee, S, Kim, MJ, Kim, JS, Oh, SY, Kim, SJ, Kwon, YH, Chung, IY, Kang, JH, Yang, DH, Kang, HJ, Yoon, DH, Kim, WS, Kim, HJ & Suh, C 2015, 'Intraocular lymphoma in Korea: The Consortium for Improving Survival of Lymphoma (CISL) study', Blood Research, vol. 50, no. 4, pp. 242-247. https://doi.org/10.5045/br.2015.50.4.242

Intraocular lymphoma in Korea : The Consortium for Improving Survival of Lymphoma (CISL) study. / Lee, Seul; Kim, Moon Jin; Kim, Jin Seok; Oh, Sung Yong; Kim, Seok Jin; Kwon, Yoon Hyung; Chung, In Young; Kang, Jung Hun; Yang, Deok Hwan; Kang, Hye Jin; Yoon, Dok Hyun; Kim, Won Seog; Kim, Hyo Jin; Suh, Cheolwon.

In: Blood Research, Vol. 50, No. 4, 01.01.2015, p. 242-247.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Intraocular lymphoma in Korea

T2 - The Consortium for Improving Survival of Lymphoma (CISL) study

AU - Lee, Seul

AU - Kim, Moon Jin

AU - Kim, Jin Seok

AU - Oh, Sung Yong

AU - Kim, Seok Jin

AU - Kwon, Yoon Hyung

AU - Chung, In Young

AU - Kang, Jung Hun

AU - Yang, Deok Hwan

AU - Kang, Hye Jin

AU - Yoon, Dok Hyun

AU - Kim, Won Seog

AU - Kim, Hyo Jin

AU - Suh, Cheolwon

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Background Intraocular lymphoma (IOL) is a rare malignant lymphoma that most closely resemblesa diffuse large B-cell lymphoma, and it is a subtype of primary central nervous systemlymphoma (PCNSL). IOL is located inside the eye in the retina, uvea, and/or optic nerve. We retrospectively analyzed IOL patient data to identify treatment patterns and survivalrates in Korea. Methods Cytological confirmation for a diagnosis of IOL was performed for all patients. The clinicaldata collected from medical records included Ann Arbor stage, International Prognostic Index, performance status, date of diagnosis, treatment modality and response, date of relapse, and date of last follow-up. Results Twenty patients who were diagnosed with IOL, between December 2007 and June 2014 at multiple centers in Korea, were included in the analysis. Four patients were diagnosed with IOL alone, not involving the CNS. Two patients with isolated IOL later developed PCNSL. Nine patients developed CNS lesions before the onset of ocular lymphoma. Fivepatients had simultaneous onset in the eye and CNS. Twelve patients were treated by intravitreal injection of methotrexate for IOL. The median progression-free survival (PFS) forpatients was 19.7 months (95% CI, 8.7-30.7 mo). The estimated 3-year overall survival(OS) for all patients was 75.1%. Conclusion Treatment for IOL patients included radiotherapy and intraocular chemotherapy. IOL patients showed favorable PFS and OS. These patients would require long-term follow-upto identify relapse and adverse effects of radiotherapy or intraocular chemotherapy.

AB - Background Intraocular lymphoma (IOL) is a rare malignant lymphoma that most closely resemblesa diffuse large B-cell lymphoma, and it is a subtype of primary central nervous systemlymphoma (PCNSL). IOL is located inside the eye in the retina, uvea, and/or optic nerve. We retrospectively analyzed IOL patient data to identify treatment patterns and survivalrates in Korea. Methods Cytological confirmation for a diagnosis of IOL was performed for all patients. The clinicaldata collected from medical records included Ann Arbor stage, International Prognostic Index, performance status, date of diagnosis, treatment modality and response, date of relapse, and date of last follow-up. Results Twenty patients who were diagnosed with IOL, between December 2007 and June 2014 at multiple centers in Korea, were included in the analysis. Four patients were diagnosed with IOL alone, not involving the CNS. Two patients with isolated IOL later developed PCNSL. Nine patients developed CNS lesions before the onset of ocular lymphoma. Fivepatients had simultaneous onset in the eye and CNS. Twelve patients were treated by intravitreal injection of methotrexate for IOL. The median progression-free survival (PFS) forpatients was 19.7 months (95% CI, 8.7-30.7 mo). The estimated 3-year overall survival(OS) for all patients was 75.1%. Conclusion Treatment for IOL patients included radiotherapy and intraocular chemotherapy. IOL patients showed favorable PFS and OS. These patients would require long-term follow-upto identify relapse and adverse effects of radiotherapy or intraocular chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=84951059877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951059877&partnerID=8YFLogxK

U2 - 10.5045/br.2015.50.4.242

DO - 10.5045/br.2015.50.4.242

M3 - Article

AN - SCOPUS:84951059877

VL - 50

SP - 242

EP - 247

JO - Blood Research

JF - Blood Research

SN - 2287-979X

IS - 4

ER -